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tion,11,12 and congestive heart failure.13,14 Increased ET-
1 levels in the systemic circulation have also been iden-
tified during cardiac surgery requiring cardiopulmonary
bypass (CPB) and cardioplegic arrest, which persists
into the postoperative period.15-21 Thus, increased pro-
duction, release, or both, of ET-1 after cardioplegic
arrest and CPB may induce deleterious effects on vascu-
lar resistance properties in a number of circulatory beds
and modify myocardial contractile performance.22-26
A number of cell types, including the cardiac
myocyte, have been shown to synthesize and release
ET-1.27-29 The synthesis and release of ET-1 into the
local extracellular environment results in the activation
of the ET-1 receptor in an autocrine-paracrine man-
ner.30-32 Increased systemic levels of ET-1 that occur
with CPB likely reflect spillover from local tissue com-
partments.33,34 However, the actual local tissue levels of
ET-1, particularly in the myocardial compartment,
remain to be defined. Moreover, whether and to what
degree myocardial ET-1 synthesis and release is influ-
enced by CPB and cardioplegic arrest remains
unknown. With the use of microdialysis techniques, it
has been demonstrated that interrogation of the myocar-
Endothelin 1 (ET-1) is a potent bioactive peptide thathas been clearly demonstrated to influence vascular
resistance properties in the systemic, pulmonary, and
coronary circulation.1-4 Moreover, exposure of myocar-
dial and isolated cardiac myocyte preparations to ET-1
has been shown to influence contractile performance.5-7
Increased ET-1 production has been reported in a num-
ber of cardiovascular disease states,8 including pul-
monary hypertension,9,10 acute myocardial infarc-
Objective: Increased systemic levels of the bioactive peptide endothelin 1
during and after cardioplegic arrest and cardiopulmonary bypass have been
well documented. However, endothelin 1 is synthesized locally, and there-
fore myocardial endothelin 1 production during and after cardiopulmonary
bypass remains unknown.
Methods: Pigs (n = 11) were instrumented for cardiopulmonary bypass, and
cardioplegic arrest was initiated. Myocardial interstitial and systemic arteri-
al levels of endothelin 1 were measured before cardiopulmonary bypass,
throughout bypass and cardioplegic arrest (90 minutes), and up to 90 min-
utes after separation from bypass. Myocardial interstitial endothelin 1 was
determined by microdialysis and radioimmunoassay.
Results: Baseline myocardial endothelin 1 levels were higher than systemic
endothelin 1 levels (25.6 ± 6.7 vs 8.3 ± 1.1 fmol/mL, P < .05). With the onset
of bypass, myocardial endothelin 1 increased by 327% ± 92% from baseline
(P < .05), which preceded the increase in systemic endothelin 1 levels.
Conclusion: Myocardial compartmentalization of endothelin 1 exists in vivo.
Cardiopulmonary bypass and cardioplegic arrest induce temporal differences
in endothelin 1 levels within the myocardial interstitium and systemic circu-
lation, which, in turn, may influence left ventricular function in the postby-
pass period. (J Thorac Cardiovasc Surg 2000;120:864-71)
C. Allyson Walker, BA
Simona C. Baicu, PhD
Aron T. Goldberg, MD
Colin E. Widener
David J. Fary
Daniel K. Almany
Adviye Ergul, MD, PhD
Fred A. Crawford, Jr, MD
Francis G. Spinale, MD, PhD
TEMPORAL ENDOTHELIN DYNAMICS OF THE MYOCARDIAL INTERSTITIUM AND SYSTEMIC 
CIRCULATION IN CARDIOPULMONARY BYPASS
From the Division of Cardiothoracic Surgery Research, Medical
University of South Carolina, Charleston, SC.
This work was supported by National Heart, Lung, and Blood
Institute grants HL-45024 and HL-56603 (F.G.S.). C. A. Walker
is a Lifeline Foundation Student Research Fellow and was sup-
ported by a Novartis Medical Student Fellowship.
Received for publication Jan 11, 2000; revisions requested March
27, 2000; revisions received May 1, 2000; accepted for publica-
tion June 28, 2000.
Address for reprints: Francis G. Spinale, MD, PhD, Cardiothoracic
Surgery, Room 625, Strom Thurmond Research Building, PO
Box 250778, 114 Doughty St, Charleston, SC 29425.
Copyright © 2000 by The American Association for Thoracic
Surgery
0022-5223/2000 $12.00 + 0 12/1/109700
doi:10.1067/mtc.2000.109700
The Journal of Thoracic and
Cardiovascular Surgery
Volume 120, Number 5
Walker et al 865
dial compartment is possible.35-37 Thus, the goals of
this study were 2-fold: (1) to investigate the temporal
production of circulating and local myocardial ET-1
during and after CPB and cardioplegic arrest and (2) to
relate systemic circulating and myocardial interstitial
ET-1 levels to left ventricular (LV) function and hemo-
dynamic parameters after CPB and cardioplegic arrest.
Methods
Instrumentation. Pigs (n = 11, 45 kg; Hambone Farms)
were instrumented to assess LV function and systemic hemo-
dynamics.38 The pigs were anesthetized with a bolus of sufen-
tanil (1 µg/kg, ESI-Elkins-Sinn Inc), and anesthesia was main-
tained with an intravenous infusion of sufentanil (0.5 µg · kg–1
· h–1). After intubation, vercuronium bromide (0.1 mg/kg,
Organon Inc, West Orange, NJ) was administered, and this
dose was repeated every 45 minutes. An arterial line (7.5F) was
placed in the carotid artery. A multilumen thermodilution
catheter (7.5F, Baxter Healthcare Corp, Irvine, Calif) was posi-
tioned in the pulmonary artery. The aortic and pulmonary
artery catheters were connected to externally calibrated trans-
ducers (Statham P231D, Gould, Inc, Oxnard, Calif). A ster-
notomy was performed, the great vessels were isolated, and a
vascular ligature was placed around the inferior vena cava to
perform transient caval occlusion.38 A precalibrated
microtipped transducer (7.5F, Millar Instruments Inc, Houston,
Tex) was placed through the LV apex and sutured in place. A
flow probe was placed around the ascending aorta and con-
nected to a digital flowmeter (HT107; Transonic Systems, Inc,
Ithaca, NY) for the continuous measurement of LV stroke vol-
ume and cardiac output. The electrocardiograms, pressure
waveforms, flow probes, and crystal signals were digitized for
subsequent analysis at a sampling frequency of 250 Hz (80386
processor; Zenith Data Systems, St Joseph, Mo).
A microdialysis probe was placed into an anterolateral sec-
tion of LV myocardium and prepared as described in the fol-
lowing section. After a 20-minute equilibration period, base-
line hemodynamics were recorded.
CPB. After collection of baseline hemodynamics and LV
function, the pigs were anticoagulated with sodium heparin
(300 U/kg) to achieve an extended clotting time of greater
than 400 seconds (ACTII, Medtronic Hemotec, Inc, Parker,
Colo). A purse-string suture was placed around the right atri-
al appendage, and a venous return cannula (34F, CR Bard Inc,
Santa Ana, Calif) was placed in the inferior vena cava. An
aortic cannula (3.8 mm, Sarns Inc, Ann Arbor, Mich) was
placed in the ascending aorta and sutured in place. The aortic
and venous cannulas were connected to a previously primed
CPB circuit containing a membrane oxygenator (Bentely
Univox Spiral Gold; Bentley Laboratories, Irvine, Calif) and
driven by a modular roller pump (Sarns 5000; 3M Healthcare,
Ann Arbor, Mich). A 12-gauge catheter (DLP Inc, Grand
Rapids, Mich) was placed at the root of the aorta for infusion
of cardioplegic solutions. After cannulation, CPB was initiat-
ed, the aorta was crossclamped, and an oxygenated, hypother-
mic, crystalloid cardioplegic solution (4°C; 500 mL; Na+, 130
mmol/L; Cl–, 109 mmol/L; K+, 24 mmol/L; Ca2+, 1.8
mmol/L; HCO3–, 30 mEq/L) was delivered through the aortic
root cannula. CPB continued for 90 minutes, and 500 mL of
cardioplegic solution was administered every 30 minutes
after the initial cardioplegic dose. During CPB, systemic
hypothermia was not used, and total flow was maintained
within 2.5 to 3.0 L/min. At the completion of the cardioplegic
arrest period, the crossclamp was removed, and reperfusion
of the myocardium was initiated. Lidocaine (2 mg/kg) was
administered at reperfusion, and if ventricular fibrillation
occurred during the initial reperfusion period, defibrillation
was performed at 20 joules with internal paddles. After a 10-
minute period to allow for resumption of adequate LV func-
tion, CPB was discontinued. No inotropic or vasoactive
agents were used at any time during the protocol, and prota-
mine was not administered. None of the animals included in
the present study required cardioversion after aortic cross-
clamp release and CPB cessation. LV function and systemic
hemodynamics were recorded at 30, 60, and 90 minutes after
crossclamp removal and separation from CPB.
Myocardial microdialysis and plasma collection.
Myocardial microdialysis studies have been performed previ-
ously for angiotensin II, and the approach was adapted for
this study.39,40 A microdialysis probe containing a 4-mm long
membrane was used (20 kd; outer diameter of probe shaft,
0.77 mm; outer diameter of probe membrane, 0.5 mm;
CMA/Microdialysis, North Chelmsford, Mass). The probe
was immersed in Krebs buffer containing 0.5% bovine serum
albumin and various concentrations of iodine 125
(125I)–labeled ET-1 (40-100 fmol/mL). The probe was then
perfused with the same buffer by a precision infusion syringe
pump (Bioanalytical Systems, West Layfayette, Ind) at vari-
ous flow rates (1, 2.5, and 5.0 µL/min). The effluent was col-
lected from the outflow tube at 30-minute sample periods.
The relative recovery of 125I-labeled ET-1 was calculated as
the percentage of radioactivity (in counts per minute) in the
perfusate to the radioactivity in the buffer. On the basis of
these in vitro calibration experiments, the relative recovery of
ET-1 at 2.5 µL/min flow rate was calculated to be 15% ± 1%
at various concentrations of 125I-labeled ET-1 (40-100
fmol/mL), and this value was used as the correction factor for
recovery of microdialysis samples.
The microdialysis probe was connected to the microdialy-
sis perfusion pump and flushed with Krebs buffer solution
containing 0.5% bovine serum albumin for 30 minutes to
allow for equilibration. This equilibration period was deter-
mined through repeated measurements taken at 30-minute
time intervals after probe insertion. The mean ET-1 values for
these collection time points were not statistically different,
and thus it was determined that an equilibration period of 30
minutes was sufficient. A microdialysis sample was collected
before CPB and cardioplegic arrest to establish baseline
myocardial interstitial ET-1 levels. Microdialysis samples
were collected at 30-minute intervals throughout CPB and up
to 90 minutes after crossclamp removal and separation from
CPB. The samples were collected into chilled microcen-
trifuge tubes and stored at –70°C until time of assay.
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Plasma ET-1 samples were obtained at the end of corre-
sponding microdialysis collection time points.
ET-1 measurement. Plasma and dialysate were first
eluted over a cation exchange column (C-18 Sep-Pak;
Waters Associates, Milford, Mass) and then dried by vacu-
um centrifugation. Recovery from the extraction procedure
was 70% ± 5% on the basis of spiked plasma and micro-
dialysis standards (0.003-32 fmol/mL). The samples were
reconstituted in 0.02 mol/L borate buffer, and a high-sensi-
tivity radioimmunoassay was performed (RPA 545,
Amersham, Arlington Heights, Ill). After incubation of
samples with 125I-labeled ET-1 and an ET-1–specific anti-
body, a charged secondary antibody was added. The final
solution was placed in a magnetic field, and bound and free
labels were separated by means of magnetic separation. To
support the range of ET-1 within the two samples, we con-
structed two sets of standards: a low range (0.003-1
fmol/mL) for the microdialysis samples and a high range
(2-32 fmol/mL) for the plasma samples. A standard linear
curve was generated by using regression analysis (Fig 1,
A). The myocardial interstitial ET-1 levels were corrected
for both the microdialysis and extraction procedures. The
interassay variation was 10% and 9% for the plasma and
microdialysis ET-1 measurements, respectively.
Data analysis. Indices of LV function, hemodynamics, and
ET-1 levels after CPB and cardioplegic arrest were initially
compared with baseline values by analysis of variance. Specific
comparisons between pre-CPB and post-CPB values were per-
formed by a Bonferroni adjusted t test. All statistical analyses
were performed by means of statistical software programs
(BMDP Statistical Software Inc, University of California Press,
Los Angeles, Calif). Results are presented as means ± SEM.
Results
Microdialysis probe storage. After the final set of
sample collections and hemodynamic measurements,
the LV region containing the microdialysis probe was
placed in a buffered formalin solution and maintained
in situ for histologic analysis. The microdialysis probe
was not located in the proximity of any major coronary
vessels and caused minimal trauma to the surrounding
tissue (Fig 1, B).
LV function and hemodynamics. Systemic hemo-
dynamics and LV function at baseline and after CPB
are presented in Table I. Mean arterial pressure, stroke
volume, and systemic vascular resistance were reduced
Fig 1. A, Linear regression analysis for microlevels of ET-1 (0.003-1 fmol/mL) using an optimized radioim-
munoassay technique. This analysis allowed for the accurate measurement of ET-1 from myocardial microdialysis
samples. The regression analysis was constructed to encompass the levels of ET-1 within the myocardial dialysate
samples. The x-axis denotes the quotient of bound and total ligand (ET-1), and the y-axis denotes the logarithmic
transformation for known ET-1 concentrations. B, Representative photomicrograph of a histologic cross section of
the myocardium with the microdialysis probe in situ. No major blood vessels were observed in the proximity of the
probe. Placement of the probe caused minimal trauma to the surrounding parenchyma, as evidenced by no extrava-
sation of red blood cells and minimal inflammatory response. (Final magnification 60×.)
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after CPB. Heart rate and mean pulmonary arterial
pressure were increased after separation from CPB.
Pulmonary vascular resistance (Fig 2) was measured
before and after CPB and cardioplegic arrest.
Pulmonary vascular resistance increased from baseline
at both 30 and 60 minutes after separation from CPB.
Arterial and myocardial interstitial ET-1. Baseline
myocardial dialysate ET-1 levels were 3-fold higher
than systemic ET-1 levels (Fig 3). Systemic ET-1 levels
were increased at 60 minutes and reached a plateau at
90 minutes during CPB and cardioplegic arrest.
Myocardial dialysate ET-1 levels also appeared to
increase during CPB; however, the high degree of vari-
ability in these values failed to reflect the intrinsic
changes in ET-1 from preparation to preparation. To
address this issue, we computed the percentage change
in systemic and myocardial dialysate ET-1 levels with
respect to baseline values (Fig 3). The relative change
in myocardial dialysate ET-1 levels increased by over
300% from baseline at 30 minutes after CPB and
induction of cardioplegic arrest. This increase in
myocardial dialysate ET-1 appeared to plateau with a
longer duration of CPB. Systemic arterial ET-1 levels
increased by over 200% at 60 minutes after cardio-
plegic arrest and CPB. The robust and early increase in
myocardial dialysate ET-1 levels at the onset of CPB
occurred before a change in plasma arterial ET-1 levels.
Discussion
Postoperative LV pump dysfunction and hemody-
namic instability can occur after cardioplegic arrest and
CPB. One potential contributory factor for this phe-
nomenon is the increased neurohormonal system activ-
ity that has been documented after CPB.41 Heightened
levels of the bioactive peptide ET-1 have been reported
to occur within the systemic circulation.15-21 Increased
Fig 2. Pulmonary vascular resistance was increased from baseline throughout the post-CPB period. Pulmonary vas-
cular resistance increased further at 60 minutes after CPB (*P < .05 vs baseline; +P < .05 vs 30 minutes after CPB).
Table I. Systemic hemodynamics and cardiac performance before and after cardioplegic arrest and CPB
Time after CPB and cardioplegic arrest (min)
Steady-state baseline 30 60 90
Heart rate (beat/min) 78 ± 4 119 ± 11* 127 ± 10* 129 ± 9*
Cardiac output (L/min) 4.2 ± 0.3 3.7 ± 0.4 3.6 ± 0.4 3.3 ± 0.4
Mean arterial pressure (mm Hg) 100 ± 3 61 ± 3* 63 ± 3* 63 ± 3*
Stroke volume (mL/beat) 39.8 ± 3.0 24.5 ± 2.9* 22.2 ± 2.6* 19.5 ± 2.6*
Mean pulmonary arterial pressure (mm Hg) 11.7 ± 1.4 17.7 ± 1.5* 22.1 ± 1.3*† 24.3 ± 1.1*†
Systemic vascular resistance (mm Hg · min–1 · mL–1) 1849 ± 167 1149 ± 121* 1231 ± 177* 1313 ± 215*
Sample size (n) 11 11 11 11
*P < .05 versus baseline.
†P < .05 versus 30 minutes after CPB and cardioplegic arrest.
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levels of ET-1 can produce a number of cardiovascular
effects, which include increased vascular resistance
and the modulation of myocardial contractility.22-26
However, the temporal dynamics of ET-1 release into
the myocardial interstitium remains unknown. By
using a porcine model of CPB and a microdialysis
approach, the present study yielded two important find-
ings. First, this study clearly demonstrates that com-
partmentalization of ET-1 within the myocardium
occurs and that these levels differ from those in the sys-
temic circulation. Second, differences in temporal ET-
1 dynamics occurred with the onset of CPB between
the myocardial interstitium and systemic circulation.
The changes in ET-1 that occur in these compartments
Fig 3. Top, Arterial plasma ET-1 levels increased from baseline during cardioplegic arrest and CPB. Plasma ET-1
levels remained elevated after CPB. Myocardial interstitial ET-1 levels were higher than plasma arterial ET-1 lev-
els at baseline and 30 minutes during CPB and appeared to increase further during and after CPB, but this did not
reach statistical significance. Bottom, The percentage change in arterial plasma ET-1 from baseline increased at 60
minutes of CPB and reached a plateau at further time points. Myocardial ET-1 levels increased at 30 minutes of
CPB, and this was higher than systemic arterial ET-1 levels. Moreover, the increase in myocardial ET-1 levels
occurred earlier than that of systemic ET-1 levels (*P < .05 vs baseline ; +P < .05 vs 60 minutes of CPB; #P < .05
vs arterial).
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during and after CPB may have important effects on
vascular resistance properties and myocardial contrac-
tility, respectively.
Several studies have reported increased circulating
ET-1 levels in the CPB setting.15-21 For example,
Knothe and associates20 reported a 2-fold increase in
ET-1 levels after CPB when compared with baseline
values. In addition, Petrossian and coworkers23 report-
ed an association between pulmonary vascular resis-
tance and increased ET-1 levels after CPB. Pulmonary
vascular resistance increased after CPB and was
accompanied by an increase in systemic ET-1 levels.
Although ET-1 causes potent vasoconstriction,29 com-
puted systemic vascular resistance was reduced after
CPB. This reduction in systemic vascular resistance
was likely caused by several computational factors.
First, despite a 50% reduction in stroke volume after
CPB, cardiac output was maintained by a compensato-
ry increase in heart rate. Second, mean arterial pressure
significantly fell after CPB, which was likely caused by
the absolute reduction in LV stroke volume. Thus the
denominator in the vascular resistance computation
remained unchanged, and the numerator fell.
Therefore, it is likely that the change in the intrinsic
compliance of the systemic vasculature after CPB was
masked by these confounding factors.
ET-1 has been shown to directly influence myocar-
dial contractile processes.6,7 Therefore, determining the
levels of ET-1 within the myocardium during and after
CPB may be of particular relevance. Past studies have
attempted to address this issue by measuring coronary
sinus levels in the setting of CPB.16,42 For example,
Hasdai and coworkers16 reported a transient fall in
coronary sinus levels during CPB, suggesting that
increased myocardial ET-1 uptake may have occurred.
The present study builds on these past reports through
direct interrogation of the myocardial compartment
through microdialysis to determine ET-1 dynamics dur-
ing and after CPB. An early and robust increase in ET-
1 levels occurred in the myocardial compartment with
the onset of CPB, which persisted into the post-CPB
period. These results suggest that increased ET-1 levels
within the myocardium after CPB may directly influ-
ence myocardial contractile function.
Under normal resting conditions, circulating levels of
ET-1 are very low. This is primarily the result of local
ET-1 production, which is sequestered in the intracellu-
lar space, as well as being bound to ET-1 receptor sys-
tems.29 Thus, increased detectable levels of ET-1 with-
in the systemic circulation most likely reflect a
spillover phenomenon from local tissue compartments.
The spillover of ET-1 into the systemic circulation with
the onset of CPB is likely caused by several factors.
First, increased synthesis and release of ET-1 can
occur, which overwhelms local ET-1–binding sites and
egresses into the systemic circulation. Second, CPB
may induce release of endogenous stores of ET-1,
which, in turn, would result in increased levels in the
systemic circulation. The present study also demon-
strated a rapid and robust increase of ET-1 within the
myocardial interstitial compartment during and after
CPB. This study did not determine the precise mecha-
nism of increased myocardial interstitial ET-1; howev-
er, this increase is most likely multifactorial. Although
the myocyte can produce and secrete ET-1,5 the abrupt
and early increase in ET-1 within the myocardial inter-
stitium after induction of cardioplegic arrest was likely
caused by the induction of a cold hyperpolarizing solu-
tion. This would cause the disassociation of ET-1 from
endogenous receptor sites. For example, Franco-
Cereceda and associates43 provided evidence that
hypothermia induced release of ET-1 from endogenous
receptors. In addition, myocardial ET-1 uptake and
binding has been reported in the bypass setting.16 In the
present study ET-1 levels remained elevated within the
myocardial interstitium throughout and after CPB,
which suggests de novo myocardial ET-1 synthesis in
the CPB setting.
A microdialysis technique to interrogate the myocar-
dial interstitial compartment has been successfully
used previously to measure bioactive peptides, as well
as determinants of high-energy phosphate produc-
tion.35,39 For example, Dell’Italia and coworkers39 used
this microdialysis technique to measure angiotensin II
levels in the myocardial interstitial compartment. More
important, the study documented a 100-fold greater
concentration of myocardial interstitial angiotensin II
versus that of the systemic circulation. In addition,
temporal angiotensin II dynamics of the systemic cir-
culation did not reflect that of the myocardium intersti-
tium. Currently, this technique is limited to the mea-
surement of low-molecular-weight molecules.44 This
approach is amendable to the measurement of ET-1
because the molecular weight of this peptide is approx-
imately 2500 d. Another important consideration of
this technique is proper placement to ensure minimal
tissue trauma. These issues were considered in the
present study through postmortem examination of the
LV region containing the microdialysis probe.
ET-1 induces biologic effects through two receptor
subtypes, ETA and ETB, both of which exist in the
myocardium.29 Stimulation of the ETA receptor results
in vasoconstriction, as well as modulation of myocar-
dial contractile properties. ETB stimulation results in
vasodilation, primarily through the production of nitric
oxide. Although the present study demonstrated a
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robust increase in ET-1 within both the myocardial
interstitial compartment and the systemic circulation,
the downstream effects of these levels on the two
receptor subtypes remains to be defined. One approach
would be through the use of ET-1 receptor antagonists,
which can be a useful tool to elucidate the potential
role of the ET-1 receptor subtypes. There are several
studies that have demonstrated beneficial hemodynam-
ic effects through the use of ET-1 receptor antagonists
in the setting of CPB23,26; however, the effects of such
blockade on myocardial contractility remain to be
defined. The present study did not precisely determine
the mechanism of increased ET-1 during and after
CPB. The biosynthesis of mature ET-1 requires cleav-
age from the proform or big ET-1.29 This enzymatic
process results in the liberation of the C-terminal pep-
tide, which may be possible to measure in the intersti-
tial space. A limitation of the present study is the lack
of information on the regional differences in ET-1 lev-
els in the CPB setting and as such warrants further
investigation. Furthermore, future studies are necessary
to more carefully define the mechanistic role that ET-1
plays in the CPB setting. However, the results of this
study clearly demonstrated the compartmentalization
of this potent bioactive peptide in the myocardium.
We thank Joseph Sistino of the Extracorporeal Technology
Program at the Medical University of South Carolina for his
aid in this project.
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